Video
Investigators evaluate out-of-pocket costs for advanced prostate cancer treatments
Author(s):
“We found that treatment-related out-of-pocket costs were 18 times higher for those patients treated with novel hormonal therapies compared to those who were just on standard ADT,” says Daniel D. Joyce, MD.
In this video, Daniel D. Joyce, MD, discusses the background and key findings from the recent Journal of Urology study, “Out-of-Pocket Cost Burden Associated With Contemporary Management of Advanced Prostate Cancer Among Commercially Insured Patients,” for which he served as a study author. Joyce is a urologic oncology fellow at Mayo Clinic, Rochester, Minnesota.
Related Videos
Related Content
